日报更新时间：
周报更新时间：06-25 22:35
今开价：0.296
最高价：0.308
成交量：964619.0
昨收价：0.282
最低价：0.25
最新价：0.252
中文名称：Corbus制药控股
英文名称：Corbus Pharmaceuticals
简介：Corbus制药控股公司（前身为JB Therapeutics公司），根据特拉华州的法律成立于2009年4月24日
电话：1-617-9630100
Corbus Pharmaceuticals Holdings, Inc.是一家 III 期临床阶段制药公司，专注于开发和商业化治疗炎症和纤维化疾病的新疗法，利用其行业领先的内源性大麻素系统靶向候选药物。Corbus Pharmaceuticals Holdings公司的主要候选产品lenabasum，是一种新型，合成，口服，选择性大麻素受体2型（CB2）激动剂，旨在解决慢性炎症和纤维化过程。Lenabasum目前正在评估系统性硬化症，囊性纤维化，皮肌炎和系统性红斑狼疮。Corbus从Jenrin Discovery LLC获得授权，全球独家开发、生产和销售候选药物，这些药物包括600多种针对内源性大麻素系统的新化合物。Corbus制药控股候选产品还包括： CRB-4001，一种第二代、外周限制性、选择性大麻素受体1型（CB1）反向激动剂，专门用于消除血脑屏障穿透和脑CB1受体占据，介导与第一代CB1反向激动剂相关的神经精神问题。 CRB-4001的潜在适应症包括NASH，原发性胆汁性胆管炎，特发性肺纤维化，放射性肺纤维化，心肌梗塞后的心肌纤维化和急性间质性肾炎等。 CRB-4001计划于2019年进行 I 期临床试验阶段，随后是美国国立卫生研究院（National Institutes of Health，NIH）资助的 II 期研究。
| 交易日期 | 交易人 | 职位 | 类型 | 交易份额 | 价格 |
|---|---|---|---|---|---|
| 2017-08-10 | Moran (Sean F) | Chief Financial Officer | Buy | 2500 | 5.91 |
| 2017-08-10 | Cohen (Yuval) | Chief Executive Officer | Buy | 1695 | 6.00 |
| 2017-08-10 | White (Barbara) | Officer | Buy | 2479 | 6.05 |
| 2017-05-10 | Hochman (David P) | Director | Buy | 3400 | 6.18 |
| 2017-05-10 | Moran (Sean F) | Chief Financial Officer | Buy | 3300 | 6.14 |
| 2017-05-10 | Holmer (Alan F) | Director | Buy | 500 | 6.23 |
| 2017-05-10 | Cohen (Yuval) | Chief Executive Officer | Buy | 3250 | 6.01 |
| 2017-05-10 | White (Barbara) | Officer | Buy | 2435 | 6.12 |
| 2017-05-10 | Catlin (Avery W) | Director | Buy | 5000 | 6.15 |
| 2017-03-16 | White (Barbara) | Officer | Buy | 4233 | 9.49 |
| 2017-03-15 | Cohen (Yuval) | Chief Executive Officer | Buy | 20000 | 1.00 |
| 2017-03-12 | Moran (Sean F) | Chief Financial Officer | Buy | 2000 | 9.60 |
| 2016-12-01 | Moran (Sean F) | Chief Financial Officer | Buy | 1500 | 7.20 |
| 2016-11-21 | White (Barbara) | Officer | Buy | 1000 | 7.75 |
| 2016-11-21 | Cohen (Yuval) | Chief Executive Officer | Buy | 1340 | 7.64 |
| 2016-11-21 | Holmer (Alan F) | Director | Buy | 1000 | 7.49 |
| 2016-11-21 | Catlin (Avery W) | Director | Buy | 2000 | 7.55 |
| 2016-11-17 | Hochman (David P) | Director | Buy | 10000 | 7.00 |
| 2016-09-07 | Moran (Sean F) | Chief Financial Officer | Buy | 30800 | 5.12 |
| 2016-08-25 | Moran (Sean F) | Chief Financial Officer | Buy | 17900 | 3.92 |
| 2016-08-21 | Hochman (David P) | Director | Buy | 1800 | 3.77 |
| 2016-08-17 | Moran (Sean F) | Chief Financial Officer | Buy | 65000 | 3.48 |
| 2016-08-16 | Moran (Sean F) | Chief Financial Officer | Buy | 83960 | 3.19 |
| 2016-08-16 | Cohen (Yuval) | Chief Executive Officer | Buy | 20000 | 1.00 |
| 2016-08-16 | White (Barbara) | Officer | Buy | 38000 | 3.15 |
| 2016-06-07 | White (Barbara) | Officer | Buy | 1935 | 3.10 |
| 2016-06-05 | Cohen (Yuval) | Chief Executive Officer | Buy | 1500 | 3.34 |
| 2016-05-31 | White (Barbara) | Officer | Buy | 2570 | 3.52 |
| 2016-05-18 | Moran (Sean F) | Chief Financial Officer | Buy | 27250 | 2.37 |
| 2016-05-17 | Cohen (Yuval) | Chief Executive Officer | Buy | 2125 | 2.40 |
| 第 页, 共 2 页 首页 上页 下页 末页 | |||||
| 机构持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| Horizons ETFs Management (Canada) Inc | 537225 | 0.83% | 537225 | -- | 2019-07-31 |
| D. E. Shaw & Co LP | 1174551 | 1.82% | 639430 | 119.49% | 2019-03-31 |
| Fidelity Management and Research Company | 1204567 | 1.87% | -210000 | -14.85% | 2019-03-31 |
| FMR Inc | 1204567 | 1.87% | -210000 | -14.85% | 2019-03-31 |
| Vanguard Investments Australia Ltd | 1806579 | 2.80% | -- | -- | 2019-07-31 |
| BlackRock Fund Advisors | 2688064 | 4.17% | 12516 | 0.47% | 2019-07-31 |
| Vanguard Group Inc | 2859541 | 4.44% | 387708 | 15.69% | 2019-03-31 |
| Knoll Capital Management LP | 4985870 | 7.74% | 923079 | 22.72% | 2019-03-31 |
| BlackRock Inc | 5030953 | 7.81% | -108940 | -2.12% | 2019-03-31 |
| Northern Trust Investments Inc | 1037330 | 1.61% | 12947 | 1.26% | 2019-07-31 |
| Fidelity SelectCo, LLC | 952867 | 1.48% | -184837 | -16.25% | 2019-07-31 |
| Morgan Stanley - Brokerage Accounts | 942508 | 1.46% | 41082 | 4.56% | 2019-03-31 |
| General American Investors Company Inc | 557400 | 0.86% | 557400 | -- | 2019-03-31 |
| Fidelity Management & Research Company | 582157 | 0.90% | 39798 | 7.34% | 2019-07-31 |
| BlackRock Advisors LLC | 627000 | 0.97% | -- | -- | 2019-07-31 |
| Northern Trust Investments N A | 630089 | 0.98% | 43100 | 7.34% | 2019-03-31 |
| Northern Trust Corp | 630089 | 0.98% | 43100 | 7.34% | 2019-03-31 |
| Geode Capital Management, LLC | 631874 | 0.98% | -453570 | -41.79% | 2019-03-31 |
| Morgan Stanley Smith Barney LLC | 894307 | 1.39% | 88855 | 11.03% | 2019-03-31 |
| State Street Corporation | 931657 | 1.45% | 47542 | 5.38% | 2019-03-31 |
| State Street Global Advisors | 501831 | 0.78% | -- | -- | 2019-06-30 |
| IFP Advisors, Inc | 1608569 | 2.50% | 102323 | 6.79% | 2018-12-31 |
| BlackRock Asset Management Canada Ltd | 1319109 | 2.05% | 541 | 0.04% | 2019-05-31 |
| ETF Managers Group, LLC | 3958561 | 6.14% | 3958561 | -- | 2018-12-31 |
| Fuller & Thaler Asset Management Inc | 262200 | 0.46% | 800 | 0.31% | 2018-12-31 |
| Raymond James Finl Svs Advisors, Inc. | 403445 | 0.70% | -24581 | -5.74% | 2018-09-30 |
| OZ Management LLC | 300800 | 0.53% | 300800 | -- | 2018-09-30 |
| BlackRock Institutional Trust Company NA | 1302406 | 2.28% | 68462 | 5.55% | 2018-06-30 |
| Millennium Management LLC | 152930 | 0.27% | 152930 | -- | 2018-06-30 |
| Wyss & Partner Asset Management & Inv AG | 105000 | 0.19% | 55000 | 110.00% | 2018-01-31 |
| Allianz Global Investors | 137624 | 0.24% | 18778 | 15.80% | 2018-03-31 |
| Renaissance Technologies Corp | 166822 | 0.29% | 166822 | -- | 2018-06-30 |
| Deutsche Bank AG | 211718 | 0.37% | 173072 | 447.84% | 2018-06-30 |
| Creative Planning Inc | 198635 | 0.35% | 19585 | 10.94% | 2018-03-31 |
| Baker Bros Advisors LP | 247450 | 0.43% | -413264 | -62.55% | 2018-06-30 |
| State Street Corp | 797955 | 1.40% | 809 | 0.10% | 2018-06-30 |
| Factor Advisors, LLC | 2871052 | 4.33% | 42715 | 1.51% | 2018-09-13 |
| Morgan Stanley & Co Inc | 135144 | 0.24% | 15158 | 12.63% | 2018-03-31 |
| Susquehanna Financial Group, LLLP | 169692 | 0.30% | 8636 | 5.36% | 2018-03-31 |
| TIAA-CREF Investment Management LLC | 124228 | 0.22% | 8572 | 7.41% | 2018-03-31 |
| BNY Mellon Investment Management | 134283 | 0.23% | -803 | -0.59% | 2018-03-31 |
| Jennison Associates LLC | 206811 | 0.36% | -18189 | -8.08% | 2018-03-31 |
| Northern Trust Asset Management | 117797 | 0.21% | 863 | 0.74% | 2018-05-31 |
| Susquehanna International Group, LLP | 169692 | 0.30% | 8636 | 5.36% | 2018-03-31 |
| Perceptive Advisors LLC | 200000 | 0.36% | -214684 | -51.77% | 2017-12-31 |
| Great Point Partners LLC | 600000 | 1.08% | 600000 | -- | 2017-12-31 |
| Atlantic Trust Group, LLC | 143500 | 0.29% | -- | -- | 2017-09-30 |
| Artal Group S A | 150000 | 0.30% | -100000 | -40.00% | 2017-09-30 |
| Cormorant Asset Management, LLC | 2500000 | 5.60% | 500000 | 25.00% | 2016-12-31 |
| Sal. Oppenheim jr. & Cie. AG & Co. KGaA | 100000 | 0.19% | 70000 | 233.33% | 2017-03-31 |
| GSA Capital Partners LLP | 100800 | 0.20% | 42000 | 71.43% | 2017-09-30 |
| Oppenheim Asset Mgmt Services S.¨¤ r.l. | 100000 | 0.20% | -- | -- | 2017-06-30 |
| Point72 Asset Management, L.P. | 189060 | 0.38% | 189060 | -- | 2017-06-30 |
| Fosun International Ltd | 700071 | 1.59% | 700071 | -- | 2016-09-30 |
| Ghost Tree Capital, LLC | 200000 | 0.45% | -100000 | -33.33% | 2016-09-30 |
| Russell Investment Management Co | 99359 | 0.22% | -- | -- | 2016-12-31 |
| Longwood Capital Partners LLC | 81302 | 0.18% | 81302 | -- | 2016-09-30 |
| Woodstock Corp | 55489 | 0.12% | 15558 | 38.96% | 2016-12-31 |
| Lawrence Allen | 1523100 | 4.00% | 4843458 | 0.10% | 1999-11-30 |
| Knoll Capital Management | 1750000 | 4.00% | 5565000 | 0.10% | 1999-11-30 |
| Mark Tepper | 2100400 | 4.00% | 6679272 | 0.10% | 1999-11-30 |
| Sumner Burstein | 3824846 | 4.00% | 12163010 | 0.20% | 1999-11-30 |
| 共同基金持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| Vanguard Health Care Index Fund | 145751 | 0.23% | -1560 | -1.06% | 2019-06-30 |
| ETFMG Alternative Harvest ETF | 7059378 | 10.95% | -- | -- | 2019-07-31 |
| Vanguard Total Stock Market Index Fund | 1806579 | 2.80% | -- | -- | 2019-06-30 |
| iShares Russell 2000 ETF | 1294961 | 2.01% | 2530 | 0.20% | 2019-07-30 |
| Vanguard Extended Market Index Fund | 728487 | 1.13% | 1870 | 0.26% | 2019-06-30 |
| iShares Nasdaq Biotechnology ETF | 639697 | 0.99% | 9986 | 1.59% | 2019-07-30 |
| BlackRock Health Sciences Opps Port | 627000 | 0.97% | -- | -- | 2019-06-30 |
| iShares Russell 2000 Growth ETF | 538046 | 0.83% | -- | -- | 2019-07-30 |
| Horizons Marijuana Life Sciences ETF | 537225 | 0.83% | 537225 | -- | 2019-06-30 |
| AdvisorShares Pure Cannabis ETF | 237478 | 0.37% | -- | -- | 2019-07-31 |
| NT R2000 Growth Index Fund - Non-Lending | 227836 | 0.35% | -9335 | -3.94% | 2019-06-30 |
| iShares Micro-Cap ETF | 150458 | 0.23% | -- | -- | 2019-07-30 |
| Northern Trust Russell 2000 Index DC NL | 157898 | 0.24% | -396 | -0.25% | 2019-06-30 |
| NT R2000 Growth Index Fund - Lending | 165411 | 0.26% | 3342 | 2.06% | 2019-06-30 |
| NT R2000 Index Fund - NL | 207989 | 0.32% | 190 | 0.09% | 2019-06-30 |
| Fidelity | 217432 | 0.34% | 39522 | 22.21% | 2019-04-30 |
| State Street Russell Small Cap | 226331 | 0.35% | -- | -- | 2019-06-30 |
| State Street Russell Small/Mid Cap | 227800 | 0.35% | -- | -- | 2019-06-30 |
| ALPS Medical Breakthroughs ETF | 134917 | 0.21% | -- | -- | 2019-06-30 |
| iShares US Small Cap ETF (CAD-Hedged) | 1123759 | 1.74% | -1890 | -0.17% | 2019-05-30 |
| Schwab Small Cap Index Fund | 110240 | 0.17% | 9313 | 9.23% | 2019-03-31 |
| Russell 2000 Index Non-Lendable Fund E | 107517 | 0.17% | 1393 | 1.31% | 2019-03-31 |
| LSF Xantos | 105000 | 0.16% | -- | -- | 2018-11-30 |
| The Vanguard - Russell 2000 Grwth Idx CF | 89680 | 0.14% | -89 | -0.10% | 2019-02-28 |
| AXA 2000 Managed Volatility Portfolio | 77998 | 0.12% | -- | -- | 2019-01-31 |
| TIAA-CREF Small-Cap Blend | 73167 | 0.13% | 11364 | 18.39% | 2018-12-31 |
| Vanguard Instl Total Stock Market Idx Fd | 69551 | 0.12% | -- | -- | 2019-01-31 |
| Master Small Cap Index Series | 63011 | 0.11% | -- | -- | 2019-01-31 |
| LVIP SSgA Small Cap Index Fund | 59092 | 0.10% | 8304 | 16.35% | 2019-01-31 |
| iShares Russell 2000 Small-Cap Index Fd | 63011 | 0.11% | 5756 | 10.05% | 2018-12-31 |
| Bridgeway Ultra Small Company Market Fd | 125915 | 0.22% | 125915 | -- | 2018-09-30 |
| Virtus LifeSci Biotech Clinical Trls ETF | 71574 | 0.13% | -- | -- | 2018-11-30 |
| Fidelity Advisor | 184837 | 0.32% | -836184 | -81.90% | 2018-07-31 |
| AdvisorShares Vice ETF | 78070 | 0.14% | -- | -- | 2018-10-31 |
| Vanguard Instl Ttl Stk Mkt Idx InstlPls | 82400 | 0.14% | -- | -- | 2018-07-31 |
| Tierra XP Latin America Real Estate ETF | 2871052 | 4.33% | 42715 | 1.51% | 2018-09-13 |
| Vanguard Total Stock Mkt Idx | 1312967 | 2.30% | 26353 | 2.05% | 2018-07-31 |
| Vanguard Extended Market Idx Inv | 666635 | 1.17% | -- | -- | 2018-07-31 |
| iShares Nasdaq Biotechnology | 641022 | 1.00% | -1221 | -0.19% | 2018-09-12 |
| BlackRock Health Sciences Opps Inv A | 559900 | 0.98% | 559900 | -- | 2018-07-31 |
| iShares Russell 2000 Growth | 472393 | 0.73% | -456 | -0.10% | 2018-09-12 |
| State Street Russell Small/Mid Cap Idx Fd Cl I | 136600 | 0.27% | 136600 | -- | 2017-06-30 |
| iShares Micro-Cap | 133248 | 0.21% | -- | -- | 2018-09-12 |
| Northern Trust Russell 2000 Index Fund - DC - Non-Lending | 121474 | 0.21% | -648 | -0.53% | 2018-07-31 |
| Vanguard Health Care ETF | 97705 | 0.17% | 828 | 0.85% | 2018-07-31 |
| Fidelity Spartan | 97055 | 0.17% | -- | -- | 2018-07-31 |
| BlackRock Extended Equity Market K | 96862 | 0.17% | 31958 | 49.24% | 2018-06-30 |
| Schwab Small Cap Index | 94500 | 0.17% | -- | -- | 2018-07-31 |
| The Vanguard Russell 2000 Growth Index | 88318 | 0.15% | -- | -- | 2018-07-31 |
| BioShares | 80342 | 0.13% | -- | -- | 2018-09-07 |
| CREF Stock R1 | 91400 | 0.16% | -- | -- | 2018-04-30 |
| BlackRock Russell 2000 | 66477 | 0.12% | 628 | 0.95% | 2018-03-31 |
| AXA 2000 Managed Volatility K | 66668 | 0.12% | -- | -- | 2018-03-31 |
| Russell US Small Cap Equity I | 99359 | 0.22% | -- | -- | 2016-12-31 |
| Vanguard Balanced Index Inv | 27092 | 0.06% | -- | -- | 2016-12-31 |
| BNY Mellon EB DL Mkt Completion | 17898 | 0.04% | -1243 | -6.49% | 2016-12-31 |
| The Vanguard Total Stock Market Index | 9187 | 0.02% | -- | -- | 2016-12-31 |
| iShares Core S&P Total US Stock Mkt | 9546 | 0.02% | -- | -- | 2017-02-07 |
| Master Extended Market Index Series | 6152 | 0.01% | -- | -- | 2016-12-31 |
| AXA/Lord Abbett Micro Cap K | 6590 | 0.01% | -- | -- | 2016-11-30 |
| SSgA U.S. Total Market Index Fd Class I | 5823 | 0.01% | 5823 | -- | 2016-09-30 |
| BlackRock Extended Equity Market Fund | 19251 | -- | 19251 | -- | 2015-09-30 |
| Fidelity® NASDAQ Composite Index® Fund | 14493 | -- | 14493 | -- | 2015-09-30 |
| The Vanguard - Total Stk Mkt Idx Trust. CF | 8700 | -- | -- | -- | 2015-10-31 |
| Vanguard US Equity Index | 3900 | -- | -- | -- | 2015-07-31 |
| AXA/Lord Abbett Micro Cap Portfolio | 3102 | -- | -- | -- | 2015-09-30 |
| Fidelity Spartan® Extended Mkt Indx Fd | 76742 | 0.20% | 37545 | 95.80% | 2015-09-30 |
| Yuval Cohen | Founder of Celsus Therapeutics Plc, Yuval Cohen is Chief Executive Officer & Director at Corbus Pharmaceuticals Holdings, Inc. and Chief Executive Officer for Corbus Pharmaceuticals, Inc. (a subsidiary of Corbus Pharmaceuticals Holdings, Inc.). He previously occupied the position of Director & Senior Vice President at Celsus Therapeutics Plc. He received an undergraduate degree from the University of Cape Town and a doctorate from the University of Paris V. |
|---|---|
| Alan F. Holmer | Currently, Alan F. Holmer occupies the position of Chairman of Corbus Pharmaceuticals Holdings, Inc. and Chairman of Corbus Pharmaceuticals, Inc. (a subsidiary of Corbus Pharmaceuticals Holdings, Inc.). He is also on the board of Food for the Hungry, Inc. In the past he was Counsel at Smith, Currie & Hancock LLP, Associate for Steptoe & Johnson LLP, Partner at Sidley & Austin, President & Chief Executive Officer for Pharmaceutical Research & Manufacturers of America and Chairman-Metropolitan Washington at The Cystic Fibrosis Foundation, Inc. Alan F. Holmer received an undergraduate degree from Princeton University and a graduate degree from Georgetown University Law Center. |
| Avery W. Catlin | Avery W. Catlin is on the board of Corbus Pharmaceuticals Holdings, Inc. and Provention Bio, Inc. and Vice President at CuraGen Corp. He previously occupied the position of Chief Financial Officer for Repligen Corp., CFO, Secretary, Treasurer & Senior Vice President at Celldex Therapeutics, Inc. and Chief Financial Officer, Secretary & SVP at AVANT Immunotherapeutics, Inc. (a subsidiary of Celldex Therapeutics, Inc.), Chief Financial Officer & VP-Operations at Endogen, Inc. and Chief Financial Officer of MediSense, Inc. Avery W. Catlin received an undergraduate degree from the University of Virginia and an MBA from Babson College. |
| Sean F. Moran | Presently, Sean F. Moran is Chief Financial & Accounting Officer of Corbus Pharmaceuticals Holdings, Inc. and Chief Financial Officer of Corbus Pharmaceuticals, Inc. (a subsidiary of Corbus Pharmaceuticals Holdings, Inc.). Mr. Moran is also on the board of Video Advertising Bureau. In his past career he occupied the position of Chief Financial Officer at Anika Therapeutics, Inc., Chief Financial Officer of Satcon Technology Corp., Chief Financial Officer & Senior Vice President at Celsion Corp., Chief Financial Officer at Echo Therapeutics, Inc. and Chief Financial Officer of Sontra Medical Corp. (a subsidiary of Echo Therapeutics, Inc.), Chief Financial Officer of Invivo Therapeutics Holdings Corp. and Chief Financial Officer at InVivo Therapeutics Corp. (a subsidiary of Invivo Therapeutics Holdings Corp.), Chief Financial Officer at Transport Pharmaceuticals, Inc. and Executive Vice President-Brand Sales at Viacom Media Networks, Inc. Mr. Moran received an undergraduate degree and an MBA from Babson College. |
| David P. Hochman | Founder of 6 different companies, which include: OPKO Biologics Ltd., BackBeat Medical, Inc. and Caliber Therapeutics, Inc. David P. Hochman is an entrepreneur and businessperson who has been at the head of 9 different companies and is Chairman & Chief Executive Officer for Orchestra BioMed, Inc., Chairman of Motus GI Holdings, Inc., President & Director at Mollie Parnis Livingston Foundation, Inc., President for Accelerated Technologies, Inc. (Texas) and President at Accelerated Technologies, Inc. David P. Hochman is also on the board of Aids Action Foundation, Corbus Pharmaceuticals Holdings, Inc. and Adgero Biopharmaceuticals Holdings, Inc. In the past Mr. Hochman was Chairman for Vital Access Corp., President & Director at BackBeat Medical, Inc. (he founded the company in 2009), Advisor at Idera Pharmaceuticals, Inc., Managing Partner at Orchestra Medical Ventures LLC, Chairman at Motus G.I. Medical Technologies Ltd., Chief Executive Officer for Spencer Trask Edison Partners LLC, Advisor at Health Dialog Services Corp., Managing Director at Augment Securities, Inc., Director at OPKO Biologics Ltd., Director at Caliber Therapeutics, Inc. and Director at FreeHold Surgical, Inc. David P. Hochman received an undergraduate degree from the University of Michigan. |
| Barbara White | Currently, Barbara White is Chief Medical Officer for Corbus Pharmaceuticals Holdings, Inc. and Chief Medical Officer of Corbus Pharmaceuticals, Inc. (a subsidiary of Corbus Pharmaceuticals Holdings, Inc.). In her past career Dr. White held the position of Associate Chief of Staff at Baltimore VA Medical Center, Head-Research & Development at Stiefel Research Institute, Inc., Vice President-Clinical Development at MedImmune LLC and Professor & Vice Chairman-Research Department at the University of Maryland School of Medicine. Dr. White received a doctorate from Perelman School of Medicine. |
| David P. Hochman | Founder of 6 different companies, which include: OPKO Biologics Ltd., BackBeat Medical, Inc. and Caliber Therapeutics, Inc. David P. Hochman is an entrepreneur and businessperson who has been at the head of 9 different companies and is Chairman & Chief Executive Officer for Orchestra BioMed, Inc., Chairman of Motus GI Holdings, Inc., President & Director at Mollie Parnis Livingston Foundation, Inc., President for Accelerated Technologies, Inc. (Texas) and President at Accelerated Technologies, Inc. David P. Hochman is also on the board of Aids Action Foundation, Corbus Pharmaceuticals Holdings, Inc. and Adgero Biopharmaceuticals Holdings, Inc. In the past Mr. Hochman was Chairman for Vital Access Corp., President & Director at BackBeat Medical, Inc. (he founded the company in 2009), Advisor at Idera Pharmaceuticals, Inc., Managing Partner at Orchestra Medical Ventures LLC, Chairman at Motus G.I. Medical Technologies Ltd., Chief Executive Officer for Spencer Trask Edison Partners LLC, Advisor at Health Dialog Services Corp., Managing Director at Augment Securities, Inc., Director at OPKO Biologics Ltd., Director at Caliber Therapeutics, Inc. and Director at FreeHold Surgical, Inc. David P. Hochman received an undergraduate degree from the University of Michigan. |
| Yuval Cohen | Founder of Celsus Therapeutics Plc, Yuval Cohen is Chief Executive Officer & Director at Corbus Pharmaceuticals Holdings, Inc. and Chief Executive Officer for Corbus Pharmaceuticals, Inc. (a subsidiary of Corbus Pharmaceuticals Holdings, Inc.). He previously occupied the position of Director & Senior Vice President at Celsus Therapeutics Plc. He received an undergraduate degree from the University of Cape Town and a doctorate from the University of Paris V. |
| Craig Millian | Craig Millian is Chief Commercial Officer of Corbus Pharmaceuticals Holdings, Inc. In his past career Mr. Millian occupied the position of Senior Vice President-Neurology & Immunology at EMD Serono, Inc. Mr. Millian received an undergraduate degree from the University of Pennsylvania and an MBA from New York University. |
| Paris Panayiotopoulos | Founder of Anthos Therapeutics, Inc., Paris Panayiotopoulos currently is Executive Chairman for Genevant Sciences Corp. and Operating Partner at Clarus Ventures LLC. He is also on the board of The Medicines Co., European Pharmaceutical Market Research Association, Corbus Pharmaceuticals Holdings, Inc. and Anthos Therapeutics, Inc. and Member of Chamber of Commerce of The United States of America. In the past Paris Panayiotopoulos occupied the position of Head-Western Europe at Merck KGaA President & Managing Director at EMD Serono, Inc. and President at Merck Serono Co., Ltd. (both are subsidiaries of Merck KGaA), President, Chief Executive Officer & Director at ARIAD Pharmaceuticals, Inc. and Principal at Eli Lilly & Co. Ltd. He received a graduate degree from Cranfield School of Management and an undergraduate degree from University College London. |
| Robert Discordia | Robert Discordia is VP-Pharmaceutical Development & Manufacturing at Corbus Pharmaceuticals Holdings, Inc. He received a doctorate from Syracuse University and an undergraduate degree from State University of New York College at Cortland. |
| Ross Lobell | Presently, Ross Lobell is Vice President-Regulatory Affairs for Corbus Pharmaceuticals Holdings, Inc. Mr. Lobell received an undergraduate degree from Lebanon Valley College. |
| John Kenneth Jenkins | John Kenneth Jenkins is on the board of Corbus Pharmaceuticals Holdings, Inc. and Principal-Drug & Biological Products at Www Greenleafhealthllc Com. In his past career Dr. Jenkins held the position of Director-New Drugs at Center for Drug Evaluation & Research and Assistant Professor at Virginia Commonwealth University Health System. He received a doctorate from the University of Tennessee. |
| Sergei Atamas | Currently, Sergei Atamas holds the position of Executive Director-Research at Corbus Pharmaceuticals Holdings, Inc. |
| Rachelle Jacques | Currently, Rachelle Jacques is Chief Executive Officer of Enzyvant, Inc. She is also on the board of Corbus Pharmaceuticals Holdings, Inc. In her past career Ms. Jacques held the position of Senior Vice President-Global Complement Franchise at Alexion Pharmaceuticals, Inc., Vice President-U S Hematology Marketing at Shire Plc and Vice President of Business Operations at Baxalta, Inc. Ms. Jacques received an undergraduate degree from Alma College. |
abu_quant
扫一扫关注阿布量化
热门推荐
全部评论 1
美股抗疫概念股盘前走强，阿索尔达生物制药涨超110%，克利夫兰生物实验室涨36%，Corbus Pharmaceuticals涨近5%，Moderna涨近3%。